Mangoceuticals Files Form 1-A for $10M Series D Preferred
Nasdaq-listed Mangoceuticals filed a Form 1-A on November 12 for up to $10 million of 8% Series D preferred. Here is how the Reg A Tier 2 offering is built.
- Filer
- Mangoceuticals, Inc.
- Form
- 1-A
- CIK
- 1938046
- On EDGAR
- 0001493152-26-051161

A Form 1-A is the offering statement a company files with the SEC to raise money under Regulation A, and a Tier 2 filing can cover up to $75 million in a 12-month period. Mangoceuticals, Inc. (Nasdaq: MGRX), a Dallas company, filed a Form 1-A on November 12, 2026, to sell a new preferred stock. Because it is a Reg A Tier 2 offering by an already listed company, the structure differs from the typical mini IPO.
What happened
The preliminary offering circular, dated November 12, covers a best-efforts offering of up to 1,000,000 shares of 8% Series D Convertible Cumulative Preferred Stock at $10.00 per share, for maximum gross proceeds of $10 million. It also qualifies up to 4,442,661 shares of common stock issuable on conversion or redemption, which is 19.99% of the 22,224,422 common shares outstanding on October 30. The cap tracks Nasdaq’s shareholder-approval rule. The last reported common stock price on November 10 was $0.19.
Nothing can be sold until the SEC qualifies the offering statement. The company has not retained an underwriter or placement agent, says its officers will not receive commissions, and will not hold subscription funds in escrow. There is no minimum amount to be sold before closings begin. The minimum investment is $2,500 (250 shares), and investors can pay by ACH, wire or the USDC stablecoin.
How the Series D works
- Dividends: 8% of the $10.00 stated value ($0.80 a year), cumulative, accruing daily and payable quarterly in cash if declared. The rate rises to 10% after certain defaults.
- Ranking: Senior to the common stock, Series B and 6% Series C preferred in liquidation, with a $15.00 liquidation preference. It does not outrank creditors.
- Conversion: Holders may convert only after the later of three years from issuance and the date shareholders approve the issuance under Nasdaq rules. The conversion price is set once, at three times the ten-day average closing price before qualification, subject to a floor tied to Nasdaq’s minimum-price rule. The circular’s example: a $0.50 average would give a $1.50 conversion price.
- Redemption: After three years the company, not the holder, may redeem at $15.00 plus accrued dividends, in cash or stock.
- Voting and trading: No general voting rights, and no plan to list the Series D.
T7X Equities, Inc. will keep the official holder records. The circular says it may also create a tokenized administrative record on the Trusted Smart Chain, but that record is not a separate security and does not establish legal ownership.
Use of proceeds
At the maximum, estimated net proceeds are about $9.95 million after roughly $50,000 of offering expenses. The largest allocation is $5.5 million for Mango & Peaches marketing and advertising, followed by $1.75 million for working capital and administrative costs, $1.25 million for software development, $1 million to market the offering, and $450,000 for additional working capital. If less is raised, the $50,000 of expenses is paid first and each category shrinks roughly in proportion.
Key terms
- Tier 2: The Regulation A tier with audited financials, ongoing reporting and a $75 million cap, without state-by-state review of the offering.
- Best efforts: The seller tries to sell the securities but does not guarantee any amount.
- Qualification: The SEC’s clearance that lets sales begin; it is not an endorsement.
- Cumulative preferred: Unpaid dividends accumulate and must be settled before common holders receive distributions.
FAQ
Is this an IPO? No. The common stock is already listed. This offering sells a new class of preferred stock directly to investors.
Can the terms change? Yes. The filing is preliminary, subject to completion or amendment, and the conversion price is fixed only on qualification.
Prepared with AI assistance from the documents listed in the margin and reviewed under our editorial policy. Not investment advice.